Pharmacokinetic profiles of doxorubicin in combination with taxanes

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 12, 2001, Pages 8-14

  Holmes, Frankie Ann ^a,c   Rowinsky, Eric Keith ^a,b  

^a US Oncology Texas Oncology   (United States)

^b CTRC Institute for Drug Development   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CIMETIDINE; CREMOPHOR; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; DOXORUBICINOL; DRUG VEHICLE; PACLITAXEL; POLYSORBATE 80; TAXANE DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BLOOD TOXICITY; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG RETENTION; DRUG SOLUBILITY; FLUID RETENTION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; MUCOSA INFLAMMATION; MYALGIA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY;

EID: 0034826478     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26435     Document Type: Conference Paper

References (27)

1. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
2. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
3. Phase II study of docetaxel in combination with doxorubicin as 1st line chemotherapy of metastatic breast cancer
4. Phase II trial of doxorubicin and docetaxel plus granulocyte-colony stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group study E1196
5. Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind
6. The taxoids: Comparative clinical pharmacology and therapeutic potential
7. Cremophor: Pharmacologic activity of an "inert" solubilizer
8. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle, Cremophor EL
9. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
10. Clinical pharmacokinetics of paclitaxel
11. Effect of the paclitaxel vehicle, Cremophor EL on the pharmacokinetics of doxorubicin and doxorubicinol in mice
12. Hypersensitivity reactions from taxol and etoposide
13. Use of the isolated perfused rat kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, Cremophor EL
14. Cholestatsis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL
15. Measurement of Cremophor EL, following Taxol plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistance phenotype
16. The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multi-drug resistant Ehrlich ascites tumor
17. Reversal of multidrug resistance phenotype by surfactants: Relationship to membrane lipid fluidity
18. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results
19. Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion
20. Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
21. Phase I trial of Adriamycin (A) + Taxol (T) in metastatic breast cancer
22. Paclitaxel plus doxorubicin in metastatic breast cancer: The Milan experience
23. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
24. Doxorubicin and Taxotere: A pharmacokinetic study of the combination in advanced breast cancer
25. Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol